生物流程市场与预测，2023年

生物过程利用细胞、细胞成分、病毒和整个生物体等生物系统来生产商业产品。此过程由两个主要阶段组成：上游生物过程和下游生物过程。在上游过程中，所需的细胞係被分离、培养并放大至最终产物所需的量。然后使用生物反应器收穫细胞，生物反应器可以是一次性的，也可以是常规的，这取决于生物体的复杂性和数量。下游加工是生产的后期阶段，上游加工结束时收穫的细胞和其他生物体经过纯化，以产生符合严格安全和品质标准的最终产品。此阶段通常采用过滤、浓缩和色谱等技术。

生物製剂是由活细胞产生的高度复杂的治疗分子，预计在未来五年内将显着超过小分子销售额。生物製品包括多种产品，包括疫苗、血液成分、基因治疗药物、重组治疗蛋白和白血球介素。这种转变是由生物製剂批准的增加以及对製造更复杂的药物分子（例如单株抗体（mAb））的关注所推动的。此外，为了解决专利聚合物疗法的高成本问题，对生物相似药的需求正在增加，预计未来五年将出现爆炸性增长。

COVID-19 大流行加快了开发时间，在某些情况下，从最初发现到研究药物批准的过程缩短至3-6 个月，中和单株抗体在14 个月内获得紧急使用授权。它也很快在世界各地以数千公斤的量批量生产用于治疗目的。这些成就凸显了该领域令人印象深刻的技术进步。生物製剂开发取得的前所未有的速度改变了整个产业，并为进一步增强技术铺平了道路，以降低製造成本，同时满足不断增长的需求。未来的成长预计将由采用连续流程、一次性系统以及与人工智慧工具相结合的先进数位化和自动化的新型小型设施来推动。从长远来看，这些创新预计将塑造该产业的发展轨迹。

本报告提供生物流程市场相关调查，彙整各产品类型，各地区的趋势，参与企业相关等资讯。

目录

• 传统的生物反应器
• 单回使用·生物反应器
• 细胞培养培养基和补充品
• 过滤与浓缩
• 流程层析法
• 实验室设备
• 最近的事业活动与市场开拓
  • 3M
  • Agilent
  • Applikon Biotechnology
  • AsahiKASEI
  • Astrea Bioseparations
  • Avantor
  • Bio-Rad
  • Corning
  • Cytiva
  • Daicel/Chiral Technologies
  • Daiso
  • Eppendorf
  • Infors HT
  • MilliporeSigma (Merck)
  • Phenomenex
  • Pierre Guerin
  • Repligen
  • Sartorius
  • Thermo Fisher
  • Tosoh
  • WR Grace

BIOPROCESSING INSTRUMENTATION MARKET ANALYSIS

Bioprocessing involves utilizing biological systems, such as cells, cell components, viruses, or entire organisms to produce commercial products. This process consists of two main stages: upstream bioprocessing and downstream bioprocessing. In the upstream segment, the target cell line is isolated, cultured, and scaled up to the desired volume for the final product. The cells are then harvested using bioreactors, which can be either single-use or conventional, depending on the complexity and volume of the organism. The downstream segment involves the later stages of production and involves purifying cells or other organisms collected at the end of the upstream stage to create a final product that meets stringent safety and quality standards. Techniques such as filtration, concentration and chromatography are commonly employed at this stage.

Biologics, the highly complex therapeutic molecules produced by living cells, are expected to significantly overtake small molecules sales over the next five years. Biologics encompass a wide range of products, including vaccines, blood components, gene therapies, recombinant therapeutic proteins, interleukins and more. This shift is driven by the increasing approval of biologics and a focus on manufacturing more intricate drug molecules such as monoclonal antibodies (mAb). Additionally, there is a growing demand for biosimilars to address the high cost of patented large molecule therapies, which are poised to witness explosive growth over the next five years.

The COVID-19 pandemic expedited development timelines, with initial discovery to investigational new drug processes shortened to 3-6 months in some cases, and neutralizing mAbs obtained emergency use authorization within 14 months. Large-scale manufacturing of thousands of kilograms for therapeutic purposes worldwide quickly followed. These achievements highlight the remarkable technological advances in the field. The unprecedented speed achieved in biologics development has transformed the industry and paved the way for further enhancements in reducing manufacturing costs while meeting rising demands. Future growth will be fueled by the adoption of new, smaller facilities that employ continuous processes, single-use systems and sophisticated digitalization and automation coupled with AI tools. These innovations are expected to shape the industry's trajectory in the long term.

SDi's “2023 Bioprocess Instrumentation Market ” observes the market dynamics and specific trends influencing the industry and analyzes their effect on sales growth for instruments and other products employed in bioprocessing. As the leading provider of market research on analytical instrumentation, SDi has crafted this report to evaluate and explain what is currently driving this important market. The bioprocessing instrument market in this report includes bioreactors, cell culture media & supplements, and chromatography. These instruments are categorized into six different technologies that represent the overall market covered in this report.

Report Overview:

Market demand segmented by product type and region along with yearly market forecasts through 2027. The market estimates have been newly updated with 2022 as the base year and estimates are provided for the following techniques:

• 1. Conventional Bioreactors
• 2. Single-Use Bioreactors
• 3. Cell Culture Media & Supplements
• 4. Filtration & Concentration
• 5. Process Chromatography
• 6. Lab Equipment

Summary of recent market developments and dynamics that are shaping our view of the market, including recent business activities.

Vendor share for participating suppliers in each technology category employed by the bioprocessing industry. Some of the top vendors in the overall market are presented below, in alphabetical order: